Furthermore, severe PTEN deficiency is associated with advanced tumor stage (70% in glioblastomas and 60% in advanced prostate cancers) and resistance to therapy, especially in targeted therapies for the receptor tyrosine kinases (RTKs) pathway (e.g., trastuzumab) [24]. Here, PTEN is linked to prostate carcinoma.